Percutaneous coronary intervention (PCI) has evolved significantly over the past four
decades. Since its inception, in-stent restenosis (ISR)—the progressive reduction in vessel …

Anti-atherogenic therapy is crucial in halting the progression of inflammation-induced intimal
hyperplasia. The aim of this concise review was to methodically assess the recent findings of …

Recent progress in bioresorbable stents (BRSs) has provided a promising alternative for
treating coronary artery disease. However, there is still lack of BRSs with satisfied …

While blood‐contacting materials are widely deployed in medicine in vascular stents,
catheters, and cannulas, devices fail in situ because of thrombosis and restenosis …

Pathological neointimal growth can develop in patients as a result of vascular injury
following percutaneous coronary intervention and coronary artery bypass grafting using …

Treatments of atherogenesis, one of the most common cardiovascular diseases (CVD), are
continuously being made thanks to innovation and an increasingly in-depth knowledge of …

Essential thrombocythemia (ET) is a classical myeloproliferative neoplasm that is
susceptible to hypercoagulable state due to impaired hemostatic system, so that thrombotic …

Despite intravascular bare metallic stents (BMS) being indispensable products in
cardiovascular surgery, they face in-stent restenosis (ISR), resulting in stent failure or …

Invasive revascularisation procedures such as coronary artery bypass grafting (CABG) and
percutaneous coronary intervention (PCI) are used to treat advanced atherosclerosis. The …

Restenosis is a clinical complication affecting 20% of people who undergo balloon
angioplasty to treat atherosclerotic plaques. Restenosis is driven by vascular smooth muscle …